Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

TELA Bio (TELA) EBIT (2018 - 2025)

Historic EBIT for Bio (TELA) over the last 8 years, with Q3 2025 value amounting to -$7.6 million.

  • Bio's EBIT rose 1933.8% to -$7.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$35.5 million, marking a year-over-year increase of 677.73%. This contributed to the annual value of -$34.1 million for FY2024, which is 2259.78% up from last year.
  • Latest data reveals that Bio reported EBIT of -$7.6 million as of Q3 2025, which was up 1933.8% from -$9.1 million recorded in Q2 2025.
  • Bio's EBIT's 5-year high stood at -$4.8 million during Q1 2024, with a 5-year trough of -$12.3 million in Q4 2023.
  • Its 5-year average for EBIT is -$9.1 million, with a median of -$9.4 million in 2022.
  • As far as peak fluctuations go, Bio's EBIT surged by 5711.75% in 2024, and later plummeted by 11699.13% in 2025.
  • Over the past 5 years, Bio's EBIT (Quarter) stood at -$7.7 million in 2021, then dropped by 23.32% to -$9.4 million in 2022, then plummeted by 30.08% to -$12.3 million in 2023, then soared by 31.96% to -$8.4 million in 2024, then increased by 9.58% to -$7.6 million in 2025.
  • Its EBIT stands at -$7.6 million for Q3 2025, versus -$9.1 million for Q2 2025 and -$10.5 million for Q1 2025.